High-throughput Automation of Holotype HLA in Routine HLA Genotyping at the EFI Annual Meeting 2017
Budapest, Hungary & Cambridge, MA May 29, 2017 (PRWEB) May 29, 2017 -- Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA™ and other Omixon products will be featured in 12 poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) in Mannheim, Germany. Additionally, Omixon’s Lunch Symposium on Wednesday will focus on Automated HLA Typing by NGS and feature three presentations from current Holotype HLA users from the EMEA region.
Among the customer presentations the most common theme is the superiority of NGS compared with legacy methods, in which rare alleles created by rare crossing over events (P118, Thomas Binder et al.) or novel alleles (P119 & P123, Xavier Lafarge et al.) can be easily determined by Holotype HLA and remain a challenge for SBT. Another popular theme is the comparison of various NGS technologies (P115, Amalia Dinou et al. and Petra Neukirchen et al.) in which the strengths of Holotype HLA are showcased against those of other vendors. Additional examples of these themes are captured in a poster presented by Omixon’s Dr. Libor Kolesar (P110), who will focus on the “Super Powers” of NGS compared to legacy technologies and highlight unique capabilities of Holotype HLA.
Omixon’s Lunch Symposium on May 31 will have three customer experience stories featuring Dr. Alexandre Walencik from the Etablissement Français du Sang (EFS), Nantes who will present their experience with Holotype HLA. “One year after, does NGS really change the world in a HLA laboratory?” Dr Walencik will their share good experiences, obstacles and their solutions with a focus on technical and organizational ways and means to encourage more labs adopt NGS for HLA such as Holotype HLA.
Dr. Reem Ameen from Kuwait University will focus on describing the validation process for introducing Holotype HLA in clinical setting and her project to extend the known HLA haplotypes in several families of Kuwaiti descent. Dr. Ameen identified haplotypes that were not among the 200 most common HLA haplotypes in any of the 5 major US populations and included 199 (17%) unique alleles, 26 rare alleles, 6 very rare alleles and 2 novels. Kuwaiti individuals carry unique HLA haplotypes that are not shared by any of the majority of subjects historically reported to the US National Marrow Donor Program (NMDP) registry - a fascinating population with tremendous potential for ongoing HLA research.
Dr. Mette Christiansen from the Aarhus University Hospital, Denmark will share their experiences on Automation of the Holotype HLA on the Beckman Biomek 4000. NGS has ushered in an era of increased capacity for HLA genotyping in terms of pooling more loci and processing larger numbers of samples thus placing ever more importance on repeatability and reproducibility. Handling of multiple samples at multiple loci simultaneously and eventually combining these into a single tube requires tightly controlled procedures, which may be achieved by automation. She will focus on the obstacles encountered and the benefits achieved in the automation process.
Marcello Scala, Director of Sales, EMEA at Omixon says, “The explosion in labs adopting Holotype HLA throughout Europe and Middle East has been truly astonishing. Even more impressive is the affection customers have for the technology due to its unrivaled ability to resolve the genotypes of complex samples for the benefit of patients and the transplant community as a whole.”
Omixon at EFI 2017
May 30 - June 02 | Omixon will be exhibiting at Booth #18 throughout the conference
May 30, 9.30am - 11am | Resolving Laboratory NGS Assay Challenges with HLA Twin
May 30, 11.30am-1pm | Resolving Complex Cases of NGS-based HLA Typing with HLA Twin
May 31, 1.30pm-2.30pm | High-throughput Automation of Holotype HLA in Clinical Routine
Omixon featured in posters
P108 | E. Bauer et al. (2017) - Full-length sequencing of a novel MICA allele variant
P110 | L. Kolesar et al. (2017) - Superpowers of NGS
P111 | J. Diegel et al. (2017) - HLA-E genotyping – the sooner the better
P115 | A. Dinou et al. (2017) - Evaluation of a commercially available HLA typing kit for NGS
P117 | T. Binder et al. (2017) - Complete human leukocyte antigen gene sequence determination combining long range polymerase chain reaction and next generation sequencing
P118 |T. Binder et al. (2017) - Whole gene sequence determination of a rare human leukocyte antigen DRB1 allele by combining long range polymerase chain reaction and next generation sequencing.
P119 | X. Lafarge et al. (2017) - Exon phasing permits identification of new alleles by NGS not detectable by Sanger sequence-based typing
P121 | P. Neukirchen et al. (2017) - NGS based HLA typing: comparison of four protocols and corresponding software
P123 | X. Lafarge et al. (2017) Validation and routine setting of HLA typing by Next Generation Sequencing using the HOLOTYPE HLA (OMIXON) kits : a multicentric experience
P127 | A. Hansen et al. (2017) - Implementing ABO genotyping into HLA sequencing workflow
P129 | L. Krammes et al. (2017) - What’s new genotyping KIR2DL5?
P145 | M. Dorak et al. (2017) - HLA-A, -B, -C typing by next generation sequencing in a sample of Turkish population
About Omixon
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA™, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 35 hospitals worldwide. Omixon’s research software, HLA Explore™ analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation.
Peter Meintjes, PhD, Omixon Biocomputing, http://www.omixon.com, +1 2039472772, [email protected]
Share this article